Dynamic visualization of RANKL and Th17-mediated osteoclast function.

Osteoclasts are bone resorbing, multinucleate cells that differentiate from mononuclear macrophage/monocyte-lineage hematopoietic precursor cells. Although previous studies have revealed important molecular signals, how the bone resorptive functions of such cells are controlled in vivo remains less well characterized. Here, we visualized fluorescently labeled mature osteoclasts in intact mouse bone tissues using intravital multiphoton microscopy. Within this mature population, we observed cells with distinct motility behaviors and function, with the relative proportion of static - bone resorptive (R) to moving - nonresorptive (N) varying in accordance with the pathophysiological conditions of the bone. We also found that rapid application of the osteoclast-activation factor RANKL converted many N osteoclasts to R, suggesting a novel point of action in RANKL-mediated control of mature osteoclast function. Furthermore, we showed that Th17 cells, a subset of RANKL-expressing CD4+ T cells, could induce rapid N-to-R conversion of mature osteoclasts via cell-cell contact. These findings provide new insights into the activities of mature osteoclasts in situ and identify actions of RANKL-expressing Th17 cells in inflammatory bone destruction.

[1]  A. Peck,et al.  Breaking old paradigms: Th17 cells in autoimmune arthritis. , 2009, Clinical immunology.

[2]  Y. Moriyama,et al.  Immunohistochemical localization of vacuolar H(+)-ATPase in osteoclasts of rat tibiae. , 1994, Archives of histology and cytology.

[3]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  E. Wagner,et al.  Reaching a genetic and molecular understanding of skeletal development. , 2002, Developmental cell.

[5]  K. Aoki,et al.  The pivotal role of the alternative NF‐κB pathway in maintenance of basal bone homeostasis and osteoclastogenesis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  J. Yamashita,et al.  Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice. , 2012, Endocrinology.

[7]  Claus Christiansen,et al.  Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity? , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  J. Visvader,et al.  Control of mammary stem cell function by steroid hormone signalling , 2010, Nature.

[9]  M. Ishii,et al.  Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis , 2010, Nature.

[10]  Y. Kadono,et al.  Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction , 2006, The Journal of experimental medicine.

[11]  K. Kavanagh,et al.  Bisphosphonates , 2007, Annals of the New York Academy of Sciences.

[12]  Samuel V Alworth,et al.  Teachable, High-Content Analytics for Live-Cell, Phase Contrast Movies , 2010, Journal of biomolecular screening.

[13]  H. Takayanagi Osteoimmunology and the effects of the immune system on bone , 2009, Nature Reviews Rheumatology.

[14]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[15]  E. Bowman,et al.  Immune regulation of bone loss by Th17 cells , 2008, Arthritis research & therapy.

[16]  S. Teitelbaum,et al.  Osteoclastic bone resorption by a polarized vacuolar proton pump. , 1989, Science.

[17]  R. Bonasio,et al.  Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. , 2005, Immunity.

[18]  G. Rodan,et al.  Mechanism of action of bisphosphonates , 2003, Current osteoporosis reports.

[19]  M. Ishii,et al.  In vivo fluorescence imaging of bone-resorbing osteoclasts. , 2011, Journal of the American Chemical Society.

[20]  Sakae Tanaka,et al.  Increased Bone Mass in Mice after Single Injection of Anti-receptor Activator of Nuclear Factor-κB Ligand-neutralizing Antibody , 2011, The Journal of Biological Chemistry.

[21]  T. Nishi,et al.  The vacuolar (H+)-ATPases — nature's most versatile proton pumps , 2002, Nature Reviews Molecular Cell Biology.

[22]  J. Windle,et al.  Paget disease of bone. , 2005, The Journal of clinical investigation.

[23]  T. Taniguchi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.

[24]  Y. Nagase,et al.  Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. , 2011, Arthritis and rheumatism.

[25]  T. Oka,et al.  Three Subunit a Isoforms of Mouse Vacuolar H+-ATPase , 2000, The Journal of Biological Chemistry.

[26]  T. Mizoguchi,et al.  Polarized osteoclasts put marks of tartrate-resistant acid phosphatase on dentin slices--a simple method for identifying polarized osteoclasts. , 2011, Bone.

[27]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[28]  Y. Kadono,et al.  Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction , 2006 .

[29]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[30]  Nobuyuki Kawamura,et al.  Direct recruitment of H+-ATPase from lysosomes for phagosomal acidification , 2009, Journal of Cell Science.

[31]  Sheila J. Jones,et al.  Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. , 1988, Endocrinology.

[32]  Sakae Tanaka,et al.  Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. , 2011, The Journal of biological chemistry.

[33]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[34]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[35]  R. Turcotte Giant cell tumor of bone. , 2006, The Orthopedic clinics of North America.

[36]  A. Yamamoto,et al.  From Lysosomes to the Plasma Membrane , 2003, Journal of Biological Chemistry.

[37]  N. Udagawa,et al.  Evaluation of Pharmaceuticals With a Novel 50‐Hour Animal Model of Bone Loss , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  D. Court,et al.  A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. , 2001, Genomics.

[39]  L. Notarangelo,et al.  Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis , 2000, Nature Genetics.